Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Can-Fite BioPharma Ltd. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 9 | 9 | 0 |
| Shares | 67.7K | 243.8K | +176.2K (+260.4%) |
| Value | $179.2K | $536.4K | +$357.2K (+199.3%) |
New holders (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 154,363 | $339.6K | 0.01% |
| Schechter Investment Advisors, LLC | 20,077 | $44.2K | 0.00% |
| Stone House Investment Management, LLC | 470 | $1.03K | 0.00% |
Sold out (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 12,047 | $31.9K |
| JPMorgan Chase & Co | 460 | $1.22K |
| Federation des caisses Desjardins du Quebec | 53 | $140 |